Titer of anti-FVIII Ig isotypes and IgG subclasses as predictors of remission and survival in 81 patients with AHA
| Variable . | Partial remission . | Complete remission . | Overall survival . | |||
|---|---|---|---|---|---|---|
| HR (95% CI) . | aHR (95% CI) . | HR (95% CI) . | aHR (95% CI) . | HR (95% CI) . | aHR (95% CI) . | |
| IgG1 | ||||||
| Negative (n = 10) | 1 | 1 | 1 | — | 1 | — |
| ≤ median (≤1:640, n = 35) | 0.71 (0.34-1.46) | 0.82 (0.37-1.81) | 1.31 (0.54-3.20) | — | 0.58 (0.18-1.88) | — |
| > median (> 1:640, n = 36) | 0.44 (0.21-0.90)* | 0.62 (0.27-1.41) | 0.81 (0.33-2.02) | — | 0.94 (0.31-2.85) | — |
| IgG2 | — | — | ||||
| Negative (n = 19) | 1 | 1 | 1 | — | 1 | — |
| ≤ median (≤1:80, n = 33) | 0.61 (0.33-1.12) | 0.59 (0.31-1.12) | 1.03 (0.51-2.08) | — | 0.90 (0.33-2.43) | — |
| > median (>1:80, n = 29) | 0.46 (0.25-0.86)* | 0.52 (0.25-1.05) | 0.69 (0.33-1.45) | — | 1.06 (0.39-2.86) | — |
| IgG3 | — | — | ||||
| Negative (n = 48) | 1 | — | 1 | — | 1 | — |
| ≤ median (≤1:80, n=17) | 1.48 (0.83-2.65) | — | 1.47 (0.78-2.76) | — | 0.69 (0.25-1.87) | — |
| > median (>1:80, n=16) | 0.84 (0.46-1.55) | — | 0.43 (0.18-1.03) | — | 1.05 (0.41-2.67) | — |
| IgG4 | — | — | ||||
| Negative (n = 2) | 1 | — | 1 | — | 1 | — |
| ≤ median (≤1:5120, n = 44) | 0.69 (0.16-2.87) | — | 0.30 (0.07-1.29) | — | 10 607 (0-∞) | — |
| > median (>1:5120, n = 35) | 0.43 (0.10-1.84) | — | 0.30 (0.07-1.28) | — | 6,644 (0-∞) | — |
| IgA | — | |||||
| Negative (n = 44) | 1 | — | 1 | 1 | 1 | 1 |
| ≤ median (≤1:80, n = 24) | 0.66 (0.38-1.15) | — | 0.47 (0.24-0.89)* | 0.46 (0.23-0.93)* | 2.42 (0.95-6.17) | 2.27 (0.82-6.24) |
| > median (> 1:80, n = 13) | 0.57 (0.29-1.15) | — | 0.15 (0.05-0.50)** | 0.15 (0.04-0.55)** | 5.76 (2.30-14.5)*** | 3.20 (1.05-9.73)* |
| Variable . | Partial remission . | Complete remission . | Overall survival . | |||
|---|---|---|---|---|---|---|
| HR (95% CI) . | aHR (95% CI) . | HR (95% CI) . | aHR (95% CI) . | HR (95% CI) . | aHR (95% CI) . | |
| IgG1 | ||||||
| Negative (n = 10) | 1 | 1 | 1 | — | 1 | — |
| ≤ median (≤1:640, n = 35) | 0.71 (0.34-1.46) | 0.82 (0.37-1.81) | 1.31 (0.54-3.20) | — | 0.58 (0.18-1.88) | — |
| > median (> 1:640, n = 36) | 0.44 (0.21-0.90)* | 0.62 (0.27-1.41) | 0.81 (0.33-2.02) | — | 0.94 (0.31-2.85) | — |
| IgG2 | — | — | ||||
| Negative (n = 19) | 1 | 1 | 1 | — | 1 | — |
| ≤ median (≤1:80, n = 33) | 0.61 (0.33-1.12) | 0.59 (0.31-1.12) | 1.03 (0.51-2.08) | — | 0.90 (0.33-2.43) | — |
| > median (>1:80, n = 29) | 0.46 (0.25-0.86)* | 0.52 (0.25-1.05) | 0.69 (0.33-1.45) | — | 1.06 (0.39-2.86) | — |
| IgG3 | — | — | ||||
| Negative (n = 48) | 1 | — | 1 | — | 1 | — |
| ≤ median (≤1:80, n=17) | 1.48 (0.83-2.65) | — | 1.47 (0.78-2.76) | — | 0.69 (0.25-1.87) | — |
| > median (>1:80, n=16) | 0.84 (0.46-1.55) | — | 0.43 (0.18-1.03) | — | 1.05 (0.41-2.67) | — |
| IgG4 | — | — | ||||
| Negative (n = 2) | 1 | — | 1 | — | 1 | — |
| ≤ median (≤1:5120, n = 44) | 0.69 (0.16-2.87) | — | 0.30 (0.07-1.29) | — | 10 607 (0-∞) | — |
| > median (>1:5120, n = 35) | 0.43 (0.10-1.84) | — | 0.30 (0.07-1.28) | — | 6,644 (0-∞) | — |
| IgA | — | |||||
| Negative (n = 44) | 1 | — | 1 | 1 | 1 | 1 |
| ≤ median (≤1:80, n = 24) | 0.66 (0.38-1.15) | — | 0.47 (0.24-0.89)* | 0.46 (0.23-0.93)* | 2.42 (0.95-6.17) | 2.27 (0.82-6.24) |
| > median (> 1:80, n = 13) | 0.57 (0.29-1.15) | — | 0.15 (0.05-0.50)** | 0.15 (0.04-0.55)** | 5.76 (2.30-14.5)*** | 3.20 (1.05-9.73)* |
Hazard ratios from Cox regression models with time to end point as dependent variable and presence/absence of immunoglobulin isotype or IgG subclass as independent variable. aHRs were adjusted for baseline variables as indicated in Table 3.
HR, hazard ratio; —, not applicable because of insignificant result in univariate analysis.
*P < .05, **P < .01, ***P < .001.